377 related articles for article (PubMed ID: 20098429)
1. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.
Li Y; Zou L; Li Q; Haibe-Kains B; Tian R; Li Y; Desmedt C; Sotiriou C; Szallasi Z; Iglehart JD; Richardson AL; Wang ZC
Nat Med; 2010 Feb; 16(2):214-8. PubMed ID: 20098429
[TBL] [Abstract][Full Text] [Related]
2. LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.
Rusz O; Papp O; Vízkeleti L; Molnár BÁ; Bende KC; Lotz G; Ács B; Kahán Z; Székely T; Báthori Á; Szundi C; Kulka J; Szállási Z; Tőkés AM
Cancer Chemother Pharmacol; 2018 Jul; 82(1):139-147. PubMed ID: 29770955
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells.
Li Y; Zhang Q; Tian R; Wang Q; Zhao JJ; Iglehart JD; Wang ZC; Richardson AL
Cancer Res; 2011 Dec; 71(24):7481-9. PubMed ID: 22037872
[TBL] [Abstract][Full Text] [Related]
4. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
de Ronde JJ; Lips EH; Mulder L; Vincent AD; Wesseling J; Nieuwland M; Kerkhoven R; Vrancken Peeters MJ; Sonke GS; Rodenhuis S; Wessels LF
Breast Cancer Res Treat; 2013 Jan; 137(1):213-23. PubMed ID: 23203637
[TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
Schindlbeck C; Mayr D; Olivier C; Rack B; Engelstaedter V; Jueckstock J; Jenderek C; Andergassen U; Jeschke U; Friese K
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1029-37. PubMed ID: 20052594
[TBL] [Abstract][Full Text] [Related]
7. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
9. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
[TBL] [Abstract][Full Text] [Related]
12. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
13. Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489 in Breast Cancer.
Soni M; Patel Y; Markoutsa E; Jie C; Liu S; Xu P; Chen H
Mol Cancer Res; 2018 Sep; 16(9):1348-1360. PubMed ID: 29784669
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-132-3p inhibits tumor malignant progression by regulating lysosomal-associated protein transmembrane 4 beta in breast cancer.
Li S; Xu JJ; Zhang QY
Cancer Sci; 2019 Oct; 110(10):3098-3109. PubMed ID: 31389121
[TBL] [Abstract][Full Text] [Related]
16. LAPTM4B Predicts Axillary Lymph Node Metastasis in Breast Cancer and Promotes Breast Cancer Cell Aggressiveness in Vitro.
Xiao M; Yang S; Meng F; Qin Y; Yang Y; Jia S; Cai X; Li C; Huang Y; Ning X
Cell Physiol Biochem; 2017; 41(3):1072-1082. PubMed ID: 28245476
[TBL] [Abstract][Full Text] [Related]
17. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
[TBL] [Abstract][Full Text] [Related]
18. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
19. The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating
Wang L; Meng Y; Xu JJ; Zhang QY
Mol Cancer Res; 2018 May; 16(5):857-868. PubMed ID: 29378908
[TBL] [Abstract][Full Text] [Related]
20. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Hatzis C; Pusztai L; Valero V; Booser DJ; Esserman L; Lluch A; Vidaurre T; Holmes F; Souchon E; Wang H; Martin M; Cotrina J; Gomez H; Hubbard R; Chacón JI; Ferrer-Lozano J; Dyer R; Buxton M; Gong Y; Wu Y; Ibrahim N; Andreopoulou E; Ueno NT; Hunt K; Yang W; Nazario A; DeMichele A; O'Shaughnessy J; Hortobagyi GN; Symmans WF
JAMA; 2011 May; 305(18):1873-81. PubMed ID: 21558518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
